Press "esc" to clear
Go to Advanced Search
Showing results 3140 of 6202
  • Embargo expired:
    4-Dec-2018 11:05 AM EST

Article ID: 704761

Protein May Slow Progression of Emphysema, Rutgers Study Finds

Rutgers University-New Brunswick

Research shows an immune response to parasitic intestinal worms provides new insights into possible treatments for the deadly disease

Released:
3-Dec-2018 10:55 AM EST

Article ID: 704836

Perosphere Pharmaceuticals' Ciraparantag Research Presented at American Society of Hematology Annual Meeting

Perosphere Pharmaceuticals Inc.

Perosphere Pharmaceuticals Inc. today announced the presentation of clinical study results demonstrating, "Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-matched Healthy Volunteers as Measured by Whole Blood Clotting Time," at the American Society of Hematology (ASH) annual meeting in San Diego on Monday, December 3, 2018.

Released:
4-Dec-2018 8:20 AM EST
GeneTherapyLab.jpg
  • Embargo expired:
    3-Dec-2018 9:30 PM EST

Article ID: 704803

Early Clinical Trial Data Show Gene Therapy Reversing Sickle Cell Anemia

Cincinnati Children's Hospital Medical Center

After over a decade of preclinical research and development, a new gene therapy treatment for Sickle Cell Anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.

Released:
3-Dec-2018 1:05 PM EST
  • Embargo expired:
    3-Dec-2018 7:30 PM EST

Article ID: 704772

Mayo Clinic researchers identify new strategies that may improve CAR-T cell therapy

Mayo Clinic

SAN DIEGO — Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy (CAR-T cell therapy) in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

Released:
3-Dec-2018 11:00 AM EST
  • Embargo expired:
    3-Dec-2018 7:00 PM EST

Article ID: 704740

Dana-Farber Scientists to Present Research on Myeloma Progression From Precursor Conditions and Novel Approaches to Treatment

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting.

Released:
3-Dec-2018 10:30 AM EST
  • Embargo expired:
    3-Dec-2018 6:30 PM EST

Article ID: 704709

Dana-Farber Scientists to Present New Research on Improving Outcomes in Stem Cell Transplantation for Myeloid Cancers

Dana-Farber Cancer Institute

Improving outcomes for patients with myeloid cancers who undergo stem cell transplantation is a focus of several studies to be presented by Dana-Farber Cancer Institute scientists at the ASH Annual Meeting.

Released:
3-Dec-2018 6:30 PM EST
Preferred9B7A5747.jpg

Article ID: 704810

Early results show promise for using genetically engineered immune cells to fight relapsed blood cancer

University of North Carolina Health Care System

At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger researchers revealed preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.

Released:
3-Dec-2018 3:05 PM EST
BurkinaFasoStudy1.jpeg

Article ID: 704812

UMSOM and Groupe De Recherche Action en Sante Begin Second Typhoid Conjugate Vaccine Study in Africa

University of Maryland Medical Center/School of Medicine

A new study has been launched Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa.

Released:
3-Dec-2018 2:05 PM EST
  • Embargo expired:
    3-Dec-2018 1:30 PM EST

Article ID: 704470

Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin Lymphoma

NYU Langone Health

A new combination of three drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.

Released:
27-Nov-2018 2:40 PM EST
2018_ReinekeLab_005-for-web.jpg

Article ID: 704799

New tumor model helps researchers treat pancreatic cancer

South Dakota State University

Patients diagnosed with pancreatic cancer face a poor prognosis because the tumor forms dense scar-like tissue that is difficult for chemotherapy drugs to penetrate, but a new model may help researchers develop new therapies.

Released:
3-Dec-2018 1:05 PM EST

Showing results 3140 of 6202

Chat now!